Fulvestrant antiestrogen for treatment of breast cancer.
Fulvestrant injection (Faslodex, AstraZeneca Pharmaceuticals LP, Wilmington, DE) is a novel estrogen receptor antagonist with no known agonist effects. Indicated for the palliative treatment of postmenopausal, endocrine-response, advanced breast cancer, the drug is well tolerated, and its most common side effect is mild gastrointestinal symptoms. Fulvestrant is administered as a once-a-month intramuscular injection in an outpatient setting. Its unique mechanism of action represents a new way to palliate breast cancer and may offer new options for women with advanced, endocrine-responsive disease.
Hancock
Christie M
CM
christiemh@sbcglobal.net
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004958:Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D020847:Estrogen Receptor Modulators / Q000627:therapeutic use; D005260:Female; D000077267:Fulvestrant; D006801:Humans
D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D020847:Estrogen Receptor Modulators; D000077267:Fulvestrant; D004958:Estradiol